Data show that the cancer vaccine Cylembio plus Keytruda demonstrated clinical improvement in progression-free survival in ...

A new cancer vaccine targeting KRAS gene mutations shows promise in preventing pancreatic and colorectal cancer recurrence in ...

Q2 2025 Earnings Call Transcript August 15, 2025 Operator: Good afternoon, ladies and gentlemen, and welcome to the Celcuity ...

A new cancer drug that can be injected directly into tumors eradicated breast cancer and melanoma metastases in a handful of ...

BLRX READ THE FULL BLRX RESEARCH REPORT BioLineRx Ltd. (NASDAQ:BLRX) reported second quarter 2025 results, producing license revenues of $304,000. Following the transition of commercialization ...

IO Biotech plans to meet with the FDA this fall to discuss the data from the phase 3 trial of Cylembio and determine next ...